Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.53
NVS's Cash to Debt is ranked higher than
59% of the 904 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. NVS: 0.53 )
NVS' s 10-Year Cash to Debt Range
Min: 0.2   Max: No Debt
Current: 0.53

Equity to Asset 0.57
NVS's Equity to Asset is ranked higher than
67% of the 820 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. NVS: 0.57 )
NVS' s 10-Year Equity to Asset Range
Min: 0.51   Max: 0.65
Current: 0.57

0.51
0.65
Interest Coverage 15.97
NVS's Interest Coverage is ranked higher than
60% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 101.95 vs. NVS: 15.97 )
NVS' s 10-Year Interest Coverage Range
Min: 13.54   Max: 30.91
Current: 15.97

13.54
30.91
F-Score: 6
Z-Score: 3.48
M-Score: -2.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 20.70
NVS's Operating margin (%) is ranked higher than
90% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.59 vs. NVS: 20.70 )
NVS' s 10-Year Operating margin (%) Range
Min: 17.81   Max: 24.34
Current: 20.7

17.81
24.34
Net-margin (%) 18.96
NVS's Net-margin (%) is ranked higher than
92% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.31 vs. NVS: 18.96 )
NVS' s 10-Year Net-margin (%) Range
Min: 15.35   Max: 31.38
Current: 18.96

15.35
31.38
ROE (%) 15.05
NVS's ROE (%) is ranked higher than
89% of the 874 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.83 vs. NVS: 15.05 )
NVS' s 10-Year ROE (%) Range
Min: 12.66   Max: 24.99
Current: 15.05

12.66
24.99
ROA (%) 8.60
NVS's ROA (%) is ranked higher than
87% of the 910 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.02 vs. NVS: 8.60 )
NVS' s 10-Year ROA (%) Range
Min: 7.25   Max: 15.7
Current: 8.6

7.25
15.7
ROC (Joel Greenblatt) (%) 54.03
NVS's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 904 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.17 vs. NVS: 54.03 )
NVS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 37.48   Max: 73.12
Current: 54.03

37.48
73.12
Revenue Growth (%) -0.20
NVS's Revenue Growth (%) is ranked higher than
62% of the 738 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. NVS: -0.20 )
NVS' s 10-Year Revenue Growth (%) Range
Min: -0.2   Max: 74.8
Current: -0.2

-0.2
74.8
EBITDA Growth (%) -7.10
NVS's EBITDA Growth (%) is ranked higher than
61% of the 694 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. NVS: -7.10 )
NVS' s 10-Year EBITDA Growth (%) Range
Min: -10   Max: 80.6
Current: -7.1

-10
80.6
EPS Growth (%) -6.40
NVS's EPS Growth (%) is ranked higher than
66% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. NVS: -6.40 )
NVS' s 10-Year EPS Growth (%) Range
Min: -6.4   Max: 83.6
Current: -6.4

-6.4
83.6
» NVS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

NVS Guru Trades in Q4 2013

Sarah Ketterer 281,741 sh (+292.43%)
Steven Cohen 8,530 sh (+84.47%)
Jim Simons 659,298 sh (+55.42%)
RS Investment Management 80,049 sh (+43.15%)
John Buckingham 84,596 sh (+1.24%)
Ken Fisher 5,787,120 sh (+1.07%)
Pioneer Investments 85,400 sh (unchged)
Mario Gabelli 10,840 sh (unchged)
Murray Stahl 29,300 sh (unchged)
Jean-Marie Eveillard 13,060 sh (unchged)
John Hussman 221,200 sh (unchged)
PRIMECAP Management 26,720,705 sh (-0.48%)
Dodge & Cox 46,485,352 sh (-0.8%)
Tweedy Browne 292,340 sh (-1%)
HOTCHKIS & WILEY 2,077,223 sh (-2.31%)
Manning & Napier Advisors, Inc 359,927 sh (-2.87%)
Irving Kahn 27,368 sh (-6.81%)
Bill Frels 3,555 sh (-7.03%)
Lee Ainslie 267,321 sh (-66.76%)
» More
Q1 2014

NVS Guru Trades in Q1 2014

Steven Cohen 12,821 sh (+50.3%)
Lee Ainslie 351,580 sh (+31.52%)
Sarah Ketterer 327,343 sh (+16.19%)
Bill Frels 4,105 sh (+15.47%)
HOTCHKIS & WILEY 2,302,956 sh (+10.87%)
Irving Kahn 28,068 sh (+2.56%)
Ken Fisher 5,889,287 sh (+1.77%)
John Buckingham 85,174 sh (+0.68%)
Murray Stahl 29,358 sh (+0.2%)
John Hussman 221,200 sh (unchged)
Pioneer Investments 85,400 sh (unchged)
Jean-Marie Eveillard 13,060 sh (unchged)
Dodge & Cox 46,441,169 sh (-0.1%)
Tweedy Browne 291,500 sh (-0.29%)
Mario Gabelli 10,740 sh (-0.92%)
RS Investment Management 76,544 sh (-4.38%)
PRIMECAP Management 24,014,586 sh (-10.13%)
Manning & Napier Advisors, Inc 314,309 sh (-12.67%)
Jim Simons 96,000 sh (-85.44%)
» More
Q2 2014

NVS Guru Trades in Q2 2014

Louis Moore Bacon 180,000 sh (New)
Dodge & Cox 51,102,219 sh (+10.04%)
Manning & Napier Advisors, Inc 332,704 sh (+5.85%)
Ken Fisher 5,969,963 sh (+1.37%)
Pioneer Investments 86,323 sh (+1.08%)
RS Investment Management 76,745 sh (+0.26%)
Murray Stahl 29,425 sh (+0.23%)
Bill Frels 4,105 sh (unchged)
Steven Cohen 69,500 sh (unchged)
Jean-Marie Eveillard 13,060 sh (unchged)
Lee Ainslie Sold Out
PRIMECAP Management 23,846,236 sh (-0.7%)
Tweedy Browne 288,825 sh (-0.92%)
John Buckingham 83,941 sh (-1.45%)
Sarah Ketterer 320,852 sh (-1.98%)
John Hussman 214,000 sh (-3.25%)
Mario Gabelli 10,240 sh (-4.66%)
Irving Kahn 26,368 sh (-6.06%)
HOTCHKIS & WILEY 649,519 sh (-71.8%)
Jim Simons 14,000 sh (-85.42%)
» More
Q3 2014

NVS Guru Trades in Q3 2014

Lee Ainslie 272,570 sh (New)
Ruane Cunniff 7,772 sh (New)
Jim Simons 285,900 sh (+1942.14%)
Irving Kahn 30,368 sh (+15.17%)
Bill Frels 4,331 sh (+5.51%)
Sarah Ketterer 334,171 sh (+4.15%)
Manning & Napier Advisors, Inc 344,881 sh (+3.66%)
Ken Fisher 6,015,233 sh (+0.76%)
John Buckingham 84,337 sh (+0.47%)
Pioneer Investments 86,502 sh (+0.21%)
John Hussman 214,000 sh (unchged)
Murray Stahl 29,425 sh (unchged)
Louis Moore Bacon Sold Out
Dodge & Cox 50,905,449 sh (-0.39%)
Mario Gabelli 10,190 sh (-0.49%)
Jean-Marie Eveillard 12,848 sh (-1.62%)
Tweedy Browne 283,983 sh (-1.68%)
PRIMECAP Management 22,239,448 sh (-6.74%)
RS Investment Management 59,008 sh (-23.11%)
Steven Cohen 21,400 sh (-69.21%)
HOTCHKIS & WILEY 9,646 sh (-98.51%)
» More
» Details

Insider Trades

Latest Guru Trades with NVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Lee Ainslie 2014-09-30 New Buy0.38%$85.25 - $94.8 $ 96.657%272570
HOTCHKIS & WILEY 2014-09-30 Reduce -98.51%0.21%$85.25 - $94.8 $ 96.657%9646
PRIMECAP Management 2014-09-30 Reduce -6.74%0.16%$85.25 - $94.8 $ 96.657%22239448
Ruane Cunniff 2014-09-30 New Buy$85.25 - $94.8 $ 96.657%7772
HOTCHKIS & WILEY 2014-06-30 Reduce -71.8%0.52%$82.51 - $90.98 $ 96.6510%649519
Lee Ainslie 2014-06-30 Sold Out 0.42%$82.51 - $90.98 $ 96.6510%0
Dodge & Cox 2014-06-30 Add 10.04%0.4%$82.51 - $90.98 $ 96.6510%51102219
PRIMECAP Management 2014-03-31 Reduce -10.13%0.26%$78.2 - $83.82 $ 96.6519%24014586
Lee Ainslie 2014-03-31 Add 31.52%0.1%$78.2 - $83.82 $ 96.6519%351580
Lee Ainslie 2013-12-31 Reduce -66.76%0.56%$72.96 - $80.39 $ 96.6525%267321
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Novartis AG

Top Guru-Bought European Stocks of the Third Quarter
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies were bought by the largest numbers of gurus over a certain period of time. By using this screener, we filtered down to see which companies based in Europe were bought by the highest number of gurus. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 23.50
NVS's P/E(ttm) is ranked higher than
86% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.00 vs. NVS: 23.50 )
NVS' s 10-Year P/E(ttm) Range
Min: 7.96   Max: 23.5
Current: 23.5

7.96
23.5
P/B 3.30
NVS's P/B is ranked higher than
72% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.58 vs. NVS: 3.30 )
NVS' s 10-Year P/B Range
Min: 1.71   Max: 4.07
Current: 3.3

1.71
4.07
P/S 4.50
NVS's P/S is ranked higher than
69% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.96 vs. NVS: 4.50 )
NVS' s 10-Year P/S Range
Min: 1.93   Max: 4.5
Current: 4.5

1.93
4.5
PFCF 26.70
NVS's PFCF is ranked higher than
91% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. NVS: 26.70 )
NVS' s 10-Year PFCF Range
Min: 7.17   Max: 26.7
Current: 26.7

7.17
26.7
EV-to-EBIT 21.54
NVS's EV-to-EBIT is ranked higher than
84% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.72 vs. NVS: 21.54 )
NVS' s 10-Year EV-to-EBIT Range
Min: 9.1   Max: 22.2
Current: 21.54

9.1
22.2
Shiller P/E 23.20
NVS's Shiller P/E is ranked higher than
89% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 148.40 vs. NVS: 23.20 )
NVS' s 10-Year Shiller P/E Range
Min: 9.38   Max: 23.79
Current: 23.2

9.38
23.79
Current Ratio 1.38
NVS's Current Ratio is ranked higher than
56% of the 891 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.41 vs. NVS: 1.38 )
NVS' s 10-Year Current Ratio Range
Min: 0.9   Max: 2.83
Current: 1.38

0.9
2.83
Quick Ratio 1.14
NVS's Quick Ratio is ranked higher than
59% of the 890 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. NVS: 1.14 )
NVS' s 10-Year Quick Ratio Range
Min: 0.66   Max: 2.48
Current: 1.14

0.66
2.48

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.80
NVS's Dividend Yield is ranked higher than
96% of the 518 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. NVS: 2.80 )
NVS' s 10-Year Dividend Yield Range
Min: 1.47   Max: 4.99
Current: 2.8

1.47
4.99
Dividend Payout 0.66
NVS's Dividend Payout is ranked higher than
75% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. NVS: 0.66 )
NVS' s 10-Year Dividend Payout Range
Min: 1.06   Max: 2.65
Current: 0.66

1.06
2.65
Dividend growth (3y) 6.10
NVS's Dividend growth (3y) is ranked higher than
81% of the 367 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.40 vs. NVS: 6.10 )
NVS' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 17.7
Current: 6.1

0
17.7
Yield on cost (5-Year) 3.95
NVS's Yield on cost (5-Year) is ranked higher than
94% of the 527 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.46 vs. NVS: 3.95 )
NVS' s 10-Year Yield on cost (5-Year) Range
Min: 2.07   Max: 7.03
Current: 3.95

2.07
7.03
Share Buyback Rate -2.70
NVS's Share Buyback Rate is ranked higher than
71% of the 634 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.50 vs. NVS: -2.70 )
NVS' s 10-Year Share Buyback Rate Range
Min: 42.5   Max: -2.7
Current: -2.7

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 13.40
NVS's Price/Tangible Book is ranked higher than
58% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.19 vs. NVS: 13.40 )
NVS' s 10-Year Price/Tangible Book Range
Min: 0.17   Max: 94.26
Current: 13.4

0.17
94.26
Price/DCF (Projected) 1.50
NVS's Price/DCF (Projected) is ranked higher than
90% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.00 vs. NVS: 1.50 )
NVS' s 10-Year Price/DCF (Projected) Range
Min: 0.64   Max: 1.47
Current: 1.5

0.64
1.47
Price/Median PS Value 1.30
NVS's Price/Median PS Value is ranked higher than
68% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.33 vs. NVS: 1.30 )
NVS' s 10-Year Price/Median PS Value Range
Min: 0.67   Max: 2.8
Current: 1.3

0.67
2.8
Price/Graham Number 3.60
NVS's Price/Graham Number is ranked higher than
74% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.77 vs. NVS: 3.60 )
NVS' s 10-Year Price/Graham Number Range
Min: 0.07   Max: 77.84
Current: 3.6

0.07
77.84
Earnings Yield (Greenblatt) 4.60
NVS's Earnings Yield (Greenblatt) is ranked higher than
83% of the 893 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. NVS: 4.60 )
NVS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.5   Max: 11
Current: 4.6

4.5
11
Forward Rate of Return (Yacktman) 2.19
NVS's Forward Rate of Return (Yacktman) is ranked higher than
77% of the 717 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.33 vs. NVS: 2.19 )
NVS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2   Max: 68.2
Current: 2.19

2
68.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, ABT » details
Traded in other countries:0HKE.UK, NOVN.Switzerland, NVSEF.USA, NOT.Germany, NOTA.Germany, NVS N.Mexico, NOVNEE.Switzerland
Novartis AG was incorporated on February 29, 1996 under the laws of Switzerland. On December 20, 1996, our predecessor companies, Ciba-Geigy AG and Sandoz AG, merged into this new entity, creating Novartis. The Company is engaged in the research, development, manufacturing and marketing of healthcare and pharmaceuticals products. The Company's portfolio includes innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. The Company's wholly-owned businesses are organized into six global operating divisions, and they report teir results in the following five segments: Pharmaceuticals: Innovative patent-protected prescription medicines, Alcon: Surgical, ophthalmic pharmaceutical and vision care products, Sandoz: Generic pharmaceuticals, Vaccines and Diagnostics: Preventive human vaccines and blood testing diagnostics, Consumer Health: OTC (over-the-counter medicines) and Animal Health. The Pharmaceuticals dividon researches, develops, manufactures, distributes and sells patented prescription medicines and is organized in the following business franchises: Primary Care, consisting of Primary Care medicines and Established Medicines; and Specialty Care, consisting of Ophthalmology, Neuroscience, Integrated Hospital Care, and Critical Care medicines. The manufacture of the products is complex and heavily regulated by governmental health authorities, which means that supply is never guaranteed. If the or their third party suppliers fail to comply with applicable regulations then there could be a product recall or other shutdown or disruption of our production activities. The Company is subject to the laws of Switzerland, in particular Swiss company and securities laws, and to the securities laws of the United States as applicable to foreign private issuers of securities.
» More Articles for NVS

Headlines

Articles On GuruFocus.com
Kahn Brothers' Third Quarter Numbers Nov 07 2014 
Tweedy Browne Global Reports its Top Five Picks of Q3 Oct 21 2014 
Zoetis Will Benefit from Industry Trends Oct 07 2014 
International Securities For A Diversified Income Portfolio Sep 23 2014 
Widely Held Guru Stocks Trading In Europe Sep 22 2014 
Why Investing Internationally Can Help Your Portfolio Sep 12 2014 
Weekly 52-Week Highs Highlight: LLY, BG, NVS, HRL Sep 07 2014 
Sarah Ketterer’s Causeway International Value Fund Reports Top Five Aug 31 2014 
I Am Sure This Pharma-Company Suits Your Portfolio Aug 28 2014 
A Strong Candidate for Investor´s Portfolios Aug 12 2014 


More From Other Websites
5 Stock-Moving Medtech Events This December Nov 28 2014
Italy Suspends Batches of Novartis Flu Vaccine After 3 Deaths Nov 28 2014
Novartis Heart-Failure Treatment to Get Speedy EU Review Nov 28 2014
1:54 am Novartis' heart failure medicine LCZ696 granted accelerated assessment by CHMP in Europe Nov 28 2014
Novartis says heart-failure drug wins faster review in Europe Nov 28 2014
GSK-Novartis deal wins US trade regulator approval Nov 27 2014
Regulatory update on transaction with Novartis Nov 27 2014
Regulatory update on transaction with Novartis Nov 26 2014
U.S. approves GSK's purchase of Novartis vaccine business-companies Nov 26 2014
Novartis selling nicotine patch to win U.S. nod for GlaxoSmithKline deal - FTC Nov 26 2014
Novartis to Divest Nicotine Patch Habitrol Nov 26 2014
Novartis selling nicotine patch to win U.S. nod for GlaxoSmithKline deal -FTC Nov 26 2014
Novartis selling nicotine patch to win U.S. nod for GlaxoSmithKline deal -FTC Nov 26 2014
Novartis selling nicotine patch to win U.S. nod for GlaxoSmithKline deal -FTC Nov 26 2014
Novartis' Multiple Myeloma Drug FDA Action Date Delayed Nov 26 2014
Novartis' Psoriasis Drug Cosentyx Backed for EU Approval Nov 24 2014
Can Partnering To Fight Hepatitis C Pay At Enanta? Nov 24 2014
Novartis Dismisses Employee who Fabricated Data in Research Papers Nov 24 2014
GSK shareholders to vote on Novartis deal on Dec. 18 Nov 24 2014
GSK shareholders to vote on Novartis deal on Dec. 18 Nov 24 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK